×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EYPT – eyepoint pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EYPT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/26
06:43 am
eypt
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
11/19
07:43 pm
eypt
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review [Yahoo! Finance]
Low
Report
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review [Yahoo! Finance]
11/19
07:13 am
eypt
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration [Yahoo! Finance]
Low
Report
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration [Yahoo! Finance]
11/19
07:00 am
eypt
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
Medium
Report
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
11/17
07:00 am
eypt
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
High
Report
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/9
07:23 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
Low
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
11/7
04:20 am
eypt
EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
11/6
11:11 am
eypt
Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $39.00. They now have an "outperform" rating on the stock.
Medium
Report
Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $39.00. They now have an "outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
07:00 am
EYPT
eyepoint pharmaceuticals, inc.
MISS
Report
-11.0%
eyepoint pharmaceuticals, inc.
8/6/2025
07:00 am
EYPT
eyepoint pharmaceuticals, inc.
MISS
Report
1.5%
eyepoint pharmaceuticals, inc.
5/7/2025
07:00 am
EYPT
eyepoint pharmaceuticals, inc.
IN-LINE
Report
-2.6%
eyepoint pharmaceuticals, inc.
3/5/2025
07:00 am
EYPT
eyepoint pharmaceuticals, inc.
MISS
Report
3.3%
eyepoint pharmaceuticals, inc.
Date
Time
Symbol
Headline
Impact
12/4
10:25 am
eypt
Form 144 EyePoint Pharmaceuticals Filed by: Lurker Nancy
Medium
Report
Form 144 EyePoint Pharmaceuticals Filed by: Lurker Nancy
12/1
04:10 pm
eypt
Form 4 EyePoint Pharmaceuticals For: Nov 26 Filed by: Lurker Nancy
Medium
Report
Form 4 EyePoint Pharmaceuticals For: Nov 26 Filed by: Lurker Nancy
11/28
01:23 pm
eypt
Form 144 EyePoint Pharmaceuticals Filed by: Lurker Nancy
Neutral
Report
Form 144 EyePoint Pharmaceuticals Filed by: Lurker Nancy
11/26
04:09 pm
eypt
Form 144 EyePoint Pharmaceuticals Filed by: Lurker Nancy
Low
Report
Form 144 EyePoint Pharmaceuticals Filed by: Lurker Nancy
11/19
07:05 am
eypt
Form 8-K EyePoint Pharmaceuticals For: Nov 19
Low
Report
Form 8-K EyePoint Pharmaceuticals For: Nov 19
11/13
09:07 am
eypt
Form SCHEDULE 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
Medium
Report
Form SCHEDULE 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
11/12
04:04 pm
eypt
Form 4 EyePoint Pharmaceuticals For: Nov 11 Filed by: Ribeiro Ramiro
Medium
Report
Form 4 EyePoint Pharmaceuticals For: Nov 11 Filed by: Ribeiro Ramiro
11/12
06:56 am
eypt
Form 144 EyePoint Pharmaceuticals Filed by: Ribeiro Ramiro
Medium
Report
Form 144 EyePoint Pharmaceuticals Filed by: Ribeiro Ramiro
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/23
EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues
23.6%
4/28 Form 8-K EyePoint Pharmaceuticals For: Apr 22 10.8%
10/17 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 10.0%
4/6 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at B. Riley from a "buy" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $4.00. 9.3%
10/15 Form 4 EyePoint Pharmaceuticals For: Oct 12 Filed by: Paggiarino Dario A. 8.4%
9/11 Eyepoint +1.9% as Guggenheim starts at Buy [Seeking Alpha] 7.1%
3/13 Form 4 EyePoint Pharmaceuticals For: Mar 12 Filed by: Elston George 7.0%
11/27 Form 8-K EyePoint Pharmaceuticals For: Nov 27 5.5%
8/7 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.130 ActVsEst 0.020 - Beat 5.1%
11/1 EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU® 4.9%
4/28 Form 8-K EyePoint Pharmaceuticals For: Apr 22 10.8%
10/17 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 10.0%
4/6 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at B. Riley from a "buy" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $4.00. 9.3%
10/15 Form 4 EyePoint Pharmaceuticals For: Oct 12 Filed by: Paggiarino Dario A. 8.4%
9/11 Eyepoint +1.9% as Guggenheim starts at Buy [Seeking Alpha] 7.1%
3/13 Form 4 EyePoint Pharmaceuticals For: Mar 12 Filed by: Elston George 7.0%
11/27 Form 8-K EyePoint Pharmaceuticals For: Nov 27 5.5%
8/7 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.130 ActVsEst 0.020 - Beat 5.1%
11/1 EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU® 4.9%
TOP News Decliners
11/7
Q3/2019 9/30/2019 EPS -0.150 ZacksConsensus -0.140 ActVsEst (0.010) - Miss
-31.1%
2/20 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock -20.8%
7/25 EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS) -16.4%
7/30 EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists -15.2%
11/9 Edited Transcript of EYPT earnings conference call or presentation 7-Nov-19 1:30pm GMT [Yahoo! Finance News] -13.5%
3/16 Form 10-K EyePoint Pharmaceuticals For: Dec 31 -13.1%
11/7 EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%
4/1 EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update -12.3%
3/5 EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress -9.7%
2/4 Form 8-K EyePoint Pharmaceuticals For: Feb 03 -8.5%
2/20 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock -20.8%
7/25 EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS) -16.4%
7/30 EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists -15.2%
11/9 Edited Transcript of EYPT earnings conference call or presentation 7-Nov-19 1:30pm GMT [Yahoo! Finance News] -13.5%
3/16 Form 10-K EyePoint Pharmaceuticals For: Dec 31 -13.1%
11/7 EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%
4/1 EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update -12.3%
3/5 EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress -9.7%
2/4 Form 8-K EyePoint Pharmaceuticals For: Feb 03 -8.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: